Core Viewpoint - The company expects to report a significant loss in net profit for 2025, despite a projected revenue of approximately 116 million yuan, indicating challenges in both military and civilian product deliveries [1] Financial Performance - Projected operating revenue for 2025 is about 116 million yuan, with an adjusted revenue of approximately 113 million yuan after excluding non-core business income [1] - The net profit attributable to shareholders is expected to be a loss between 35 million yuan and 43 million yuan, representing a reduction in losses of 32.96 million yuan to 24.96 million yuan [1] - The net profit after deducting non-recurring gains and losses is projected to be a loss between 53.85 million yuan and 61.85 million yuan, with a reduction in losses of 28.52 million yuan to 20.52 million yuan [1] Revenue Decline Factors - The decrease in revenue is primarily due to delays in the delivery of military products, with some R&D products undergoing system integration and testing, failing to meet acceptance criteria [1] - Certain models of mass-produced products did not complete delivery within the reporting period, contributing to the revenue decline [1] - Civilian product contracts saw a year-on-year decrease in orders during the reporting period, further impacting revenue [1] Cost Management - During the reporting period, the company's period expenses decreased by approximately 24% [1] - Government subsidies and tax refunds related to operations increased by about 102% year-on-year, providing some financial relief [1] - Despite a 32% decline in revenue, the combination of reduced expenses and increased government support led to a smaller net loss than previously anticipated [1]

Core Viewpoint - The company Baiotai (688177.SH) expects to reduce its losses in 2025 compared to the previous year, with projected net profit attributable to shareholders ranging from -280 million to -390 million yuan, a reduction in losses by 120 million to 230 million yuan [1] Financial Performance - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, to be between -380 million and -490 million yuan, reducing losses by 65.61 million to 176 million yuan [1] - The expected operating revenue for the reporting period is between 900 million and 970 million yuan, an increase of 157 million to 227 million yuan compared to the same period last year [1] Market Expansion - The sales of Adalimumab injection (Geleli®) and Tocilizumab injection (Shiruili®) have steadily increased compared to the same period last year, contributing to the company's revenue growth [1] - The company has launched Ustinumab injection (STARJEMZA®) in the U.S., leading to growth in both licensing income and sales revenue [1]